The ORBIT trial is part of a worldwide search for a functional cure of HIV. One such cure strategy aims to reverse HIV in the reservoir from latency by increasing cell-associated HIV-RNA, which will lead to increased antigen presentation, trigger immune recognition, and facilitate the elimination of reservoir cells (so-called 'shock and kill' approach to HIV cure). Participants of the trial are adults with HIV with undetectable viral load that are able to give informed consent to participate in the trial, in total 49 patients will be recruited. The investigational medical compounds in this trial are panobinostat, lenalidomide and pyrimethamine. These are all licensed drugs for other conditions. Participants of this trial will receive a single dose of the IMPs, either as monotherapy or as combination therapy. Sampling will be performed before, during and after medical treatment to evaluate latency reversal, reservoir reduction and safety endpoints. Patients will be recruited from the Erasmus MC, Amsterdam university Medical Center and the University Medical Center Utrecht.

Start Date01 Apr 2024

Sponsor / Collaborator

Erasmus MC

NCT05324501

/ TerminatedPhase 1

Phase I Open Label Ascending Dose Study to Assess the Feasibility and Safety of Intermittent Infusions of MTX110 Administered by Convection-Enhanced Delivery (CED) in Patients With Recurrent Glioblastoma (rGBM) (MAGIC-G1)

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

Start Date19 Oct 2022

Sponsor / Collaborator

Biodexa Pharmaceuticals Plc

NCT05725200

/ RecruitingPhase 2IIT

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Start Date27 Sep 2022

Sponsor / Collaborator

Oslo universitetssykehus HF

100 Clinical Results associated with Panobinostat lactate

100 Translational Medicine associated with Panobinostat lactate

100 Patents (Medical) associated with Panobinostat lactate

1,930

Literatures (Medical) associated with Panobinostat lactate

01 Apr 2025·JOURNAL OF CONTROLLED RELEASE

Multidrug micelles and sonopermeation for chemotherapy co-delivery to brain tumors

Article

Author: Ries, Mario ; Hennink, Wim E ; Storm, Gert ; Buhl, Eva Miriam ; Rix, Anne ; Lammers, Twan ; Metselaar, Josbert ; Klinkenberg, Geir ; Koletnik, Susanne ; Kiessling, Fabian ; Schmid, Ruth ; Moonen, Chrit ; Dasgupta, Anshuman ; Shalmani, Armin Azadkhah ; May, Jan-Niklas ; Besse, Helena C ; van Vuurden, Dannis ; Moeckel, Diana ; Hark, Christopher ; Shi, Yang ; Peña, Quim ; Mihyar, Rahaf

Brain tumors are difficult to target and treat. The blood-brain barrier (BBB) limits drug delivery to pathological sites, and standard mono-chemotherapy typically results in suboptimal efficacy and development of drug resistance. We here set out to load a synergistic drug combination in polymeric micelles, and combined them with ultrasound- and microbubble-mediated BBB opening in glioma models in mice. Via high-throughput screening of various chemotherapy combinations in different glioma cell lines, valrubicin and panobinostat were identified as a synergic drug combination and co-loaded in mPEG-b-p(HPMAm-Bz)-based polymeric micelles. Intravenous administration of double-drug micelles showed good tolerability and resulted in significant tumor growth inhibition in mice with subcutaneous GL261 gliomas. In orthotopically inoculated patient-derived HSJD-DIPG-007 diffuse intrinsic pontine gliomas, notoriously known to have an intact BBB and poor drug responsiveness, we provide initial experimental evidence showing that multidrug micelles plus sonopermeation can help to improve treatment efficacy. Our work exemplifies that synergistic drug combinations can be efficiently co-loaded in polymeric micelles, and that advanced nanosonochemotherapy combination regimens hold promise for the treatment of hard-to-treat brain cancers.

01 Mar 2025·CANCER LETTERS

Machine learning-based lactate-related genes signature predicts clinical outcomes and unveils novel therapeutic targets in esophageal squamous cell carcinoma

Article

Author: Xin, Lei ; Yu, Chuting ; Wang, Wei ; Bian, Yan ; Wang, Luowei ; Xu, Yusi ; Gao, Ye ; Lin, Han ; Jiao, Yunfei

Esophageal squamous cell carcinoma (ESCC), a predominant subtype of esophageal cancer, typically presents with poor prognosis. Lactate is a crucial metabolite in cancer and significantly impacts tumor biology. Here, we aimed to construct a lactate-related prognostic signature (LPS) for predicting prognosis in ESCC and uncovering potential therapeutic targets. We designed a computational framework to identify lactate-related genes (LRGs) and applied machine-learning to generate an optimal LPS model from 103 combinations. The LPS was evaluated for its predictive accuracy regarding patient prognosis, chemotherapy, radiotherapy, and immunotherapy. Analysis also covered genomic and proteomic traits linked to LPS-defined subtypes. The LPS model demonstrated robust and reliable accuracy in predicting survival outcomes in patients with ESCC. Patients with low LPS scores exhibited a more favorable prognosis and an enhanced response to both chemotherapy and radiotherapy. Conversely, patients with high LPS scores exhibited increased sensitivity to BI-2536 and panobinostat. Furthermore, a low LPS score was associated with better prognosis in multiple immunotherapy datasets across cancer types. Genetic amplifications and deletions were detected more frequently in the high-LPS than in the low-LPS group; however, no significant correlation was observed with the tumor mutation burden. Knockdown of GATM, a key LRG, significantly inhibited cell viability, proliferative capacity, and migration and invasion abilities in ESCC cell lines. In conclusion, the LPS score can be used to predict the prognosis of patients with ESCC and facilitate a more precise approach for selecting patients likely to respond to treatment.

01 Feb 2025·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The identification of insect specific iAANAT inhibitors

Article

Author: Sabbagh, Christian ; Radulovic, Peter W ; Henry, Gabrielle ; Merkler, David J ; Suarez, Gabriela ; Hawley, Aidan J ; Bhandari, Suzeeta ; Scearbo, Matthew ; Holets, Tyler ; Borisova, Natalia

An important aspect of food security is the development of innovative insecticides, particularly ones that specifically target insect pests and exhibit minimal toxicity to mammals. The insect arylalkylamine N-acyltransferases (iAANATs) could serve as targets for novel insecticides that satisfy these criteria. There exists a wealth of structural and biochemical information for the iAANATs and iAANAT knockdown experiments show that these enzymes are critical to insect health. Herein, we have expressed, purified, and characterized two new iAANATs, one from Apis mellifera (honey bee, AmNAT1) and another from Diaphorina citri (Asian citrus psyllid, DcNAT). We discovered that diminazene, a compound used to treat livestock for trypanosomiasis and babesiosis, inhibits AmNAT1, DcNAT, and D. melanogaster DmAgmNAT with modest affinity, K_i values ranging from 0.8 μM to 200 μM. We found a series of guanidines, amidines, and a hydroxamate, structurally related to diminazene, also inhibit the iAANATs, including camostat, gabexate, nafamostate, and panobinostat. Significantly, we found DmAgmNAT is far more susceptible to inhibition by four of these five of these compounds. In particular, camostat, nafamostat, and gabexate inhibit DmAgmNAT with K_i values of 0.2-30 μM, but no inhibition of AmNAT1 and DcNAT was observed at 500 μM for any of the three. These results show that a species-specific inhibitor targeted against an iAANAT is a real possibility. Also, we report that adipoyl-CoA is a substrate for AmNAT1 and DcNAT and that succinoyl-CoA is a substrate for DcNAT. These results contribute to a growing body of data suggesting that N-dicarboxyacyl-amines are metabolites in insects and other organisms.

News (Medical) associated with Panobinostat lactate

12 Feb 2025

·www.globenewswire.com

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that the US Food and Drug Administration (“FDA”) has granted Fast Track designation for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). Fast track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only treatment option is surgical resection of the colon and/or rectum. Data from the Phase 2 study of eRapa in FAP showed eRapa to be safe and well-tolerated with a median 17% reduction in total polyp burden at 12 months compared with baseline and an overall 75% non-progression rate. Patients in cohort 2 experienced an 89% non-progression rate and 29% median reduction in polyp burden at 12 months compared with baseline. The dosing given to cohort 2 – daily every other week -- is the preferred dosage regimen for the upcoming registrational Phase 3 study. FAP is characterized as a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP universally leads to cancer of the colon and/or rectum. There is a significant hereditary component to FAP with a reported prevalence of one in 5,000 to 10,000 in the US1 and one in 11,300 to 37,600 in Europe2. Biodexa has received US FDA Orphan Drug designation for eRapa in FAP and plans to seek a similar designation in Europe. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis3. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035. 1. www.rarediseases.org 2. www.orpha.net 3. Tian et al., mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy, Int J Mol Sci. 2019 Feb; 20(3): 755 Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultOrphan DrugFast TrackDrug Approval

12 Nov 2024

·www.globenewswire.com

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that the Company has been formally notified that the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). As previously disclosed, the Company received notice from Nasdaq on August 27, 2024, informing the Company that it was not in compliance with the Minimum Bid Price Requirement. On October 14, 2024, the Panel granted the Company’s request for an exception to demonstrate compliance with the Minimum Bid Price Requirement for continued listing through October 31, 2024. The Company remains subject to a discretionary panel monitor through February 24, 2025, and is required to provide prompt notification during this exception period of any significant events that occur during this time that may affect the Company’s compliance with Nasdaq requirements. About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com. Forward-Looking StatementsCertain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.

07 Nov 2024

·www.globenewswire.com

Notice of General Meeting

November 7, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 22 November 2024 at 13:00 GMT was posted to shareholders yesterday. The Board of Directors is proposing two resolutions: Ordinary Resolution 1. That, subject to and conditional on the passing of Resolution 2, each of the issued ordinary shares of £0.001 each in the capital of the Company be subdivided and redesignated into one ordinary share of £0.00005 each and 19 C deferred shares of £0.00005 each (such C deferred shares having the rights and being subject to the restrictions set out in the articles of association of the Company adopted pursuant to Resolution 2). Special Resolution 2. That, subject to and conditional on the passing of Resolution 1, the draft articles of association tabled at the meeting, initialled by the Chairman, and available on the Company’s website, www.biodexapharma.com and labelled the ‘New Articles’, be approved and adopted as the new articles of association of the Company in substitution for and to the entire exclusion of the Company’s existing articles of association. The purpose of the Resolutions is to lower the par value of the ordinary shares and allow the Company to issue ordinary shares above par value. Neither the number of ordinary shares outstanding nor the number of American Depositary Shares will change as a result of passing of the Resolutions. About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com. Forward-Looking StatementsCertain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.

100 Deals associated with Panobinostat lactate

External Link

KEGG	Wiki	ATC	Drug Bank
D10019	Panobinostat lactate	L01XX42	DB06603

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	US	Secura Bio, Inc.Startup	23 Feb 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hodgkin's Lymphoma	Phase 3	US	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	AU	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	BE	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	BR	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	CA	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	FR	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	DE	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	IL	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	IT	Novartis Pharmaceuticals Corp.	01 Jun 2010
Hodgkin's Lymphoma	Phase 3	NL	Novartis Pharmaceuticals Corp.	01 Jun 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05324501 (MAGIC-G1, GlobeNewswire) Manual	Phase 1	Recurrent Glioblastoma	4	MTX110 (Cohort A)	vjypnaqhcx(dvktmiuumt) = dlqunvolld cqoadfdzib (pyrjejpdqa )	Positive	04 Oct 2024
NCT02654990 (PANORAMA 3 \| PANORAMA_3, CTgov)	Phase 2	Multiple Myeloma	248	Panobinostat (Arm A - Panobinostat (20 mg, TIW))	qdsmgavvsb(kbfhwzogln) = wubbqpbqqs kvtrdmrvmx (rodlwnlxos, ilydbvjhyy - wodwjvdxfw) View more	-	12 Jul 2024
NCT02654990 (PANORAMA 3 \| PANORAMA_3, CTgov)	Phase 2	Multiple Myeloma	248	Panobinostat (Arm B - Panobinostat (20 mg, BIW))	qdsmgavvsb(kbfhwzogln) = glvswbiodw kvtrdmrvmx (rodlwnlxos, dpuxgwdvhb - oshlpkifwi) View more	-	12 Jul 2024
NCT04264143 (Biospace) Manual	Phase 1	Diffuse Midline Glioma	9	MTX110	vrtgvtrxlr(aebrdbsixs) = waxlbyjdaq uwmqzzgjkw (rllrdyntwh, 8 - 20) View more	Positive	02 Jul 2024
NCT02471430 (ACTIVATE, CTgov)	Phase 1/2	HIV Seropositivity	17	Panobinostat (Arm A)	dydznxomtn(qpwumhhsnv) = jqrmufviur kqzpfwnjas (lkzqgqxuev, ggzxpthaac - oxjihougoq) View more	-	28 Feb 2024
NCT02471430 (ACTIVATE, CTgov)	Phase 1/2	HIV Seropositivity	17	Panobinostat+Pegylated Interferon-alpha2a (Arm B)	dydznxomtn(qpwumhhsnv) = xmtqazmoye kqzpfwnjas (lkzqgqxuev, oqkyhzjhsq - tirovxvdtm) View more	-	28 Feb 2024
NCT04264143 (GlobeNewswire) Manual	Phase 1	Diffuse Midline Glioma	9	MTX110	wkqszbnnek(nizpjobvgw) = lhzfzsrgyt gubnmwpyte (pcvukwhjue )	Positive	23 Feb 2024
NCT02506959 (Tandem Meetings ASTCT and CIBMTR2023)	Phase 2	Bone Marrow Neoplasms del(17p) \| t(4;14) \| t(14;16) ... View more	80	Pano/GemBuMel	rovryhldcy(zimshkaurs) = rlmgzbpsqx jdughtstvj (rhwjbarcxo ) View more	Positive	01 Feb 2023
NCT03256045 (CTgov)	Phase 2	Recurrent Multiple Myeloma \| Relapse multiple myeloma \| Refractory Multiple Myeloma	9	Panobinostat+Carfilzomib+Dexamethasone	pptlcgrtpb(qhglhokhbe) = pphwaboxmn ccxftxesqw (iekffgfabp, jjhcietvpk - ygpquoyuwv) View more	-	09 May 2022
NCT03566199 (PNOC015, CTgov)	Phase 1/2	Diffuse Intrinsic Pontine Glioma	7	MTX110	kczxpberln(gsavagdwdk) = jbipfbvujn vewslifphx (bmypuwguhp, dtlzveqkeq - bktwmpnwnv) View more	-	25 Feb 2022
NCT01496118 (CTgov)	Phase 1/2	Relapse multiple myeloma \| Refractory Multiple Myeloma	80	panobinostat+Carfilzomib (Dose Level 1)	bqwbzgtvek(xlaxeiyyax) = zcyasiwovy vqklablrpc (rpspmxquoj, iuazehrmxj - fhaspxudaz) View more	-	02 Feb 2022
NCT01496118 (CTgov)	Phase 1/2	Relapse multiple myeloma \| Refractory Multiple Myeloma	80	panobinostat+Carfilzomib (Dose Level 2)	bqwbzgtvek(xlaxeiyyax) = azwnjthvuv vqklablrpc (rpspmxquoj, kzagbanaqv - cfcbgbrxzm) View more	-	02 Feb 2022
ASTRO2021	Not Applicable	Diffuse Intrinsic Pontine Glioma	-	Panobinostat	nweajzxzzs(vhiwjeycwe) = tkfuluwohs ojnmzwghel (shhntvfhih )	-	01 Nov 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis